Technology Platforms

Creative Biolabs employs messenger RNA (mRNA) to unleash and boost the immune response against a tumor or infectious agent. Researches show that this approach results in long-lasting clinical remission in cancer patients and protective immunity against infections. Here we make a brief introduction about two technologies widely used in mRNA research.

LPR Technology

Currently, mRNA-based vaccines are being developed for treating various diseases including cancers. For this purpose, synthetic or in vitro transcribed (IVT) mRNA encoding tumor antigen offers several advantages over plasmid DNA encoding tumor antigen including better delivery and security. Liposomes/Polymer/mRNA ternary complexes termed lipoplyplexes (LPR) can be used to deliver mRNA encoding antigen in vivo. Studies reported the preparation of mannosylated mRNA nanoparticles (Man-LPR) loaded with mRNA encoding a melanoma antigen MART-1. Immunization with LPR instigated extremely potent T-cell responses and showed superior effectiveness in controlling tumor growth compared to intravenous immunization with antigen mRNA electroporated DCs.

Fig.1 The illustration of LPR composition. (Pichon, 2013)

Advantages

• Combining the beneficial properties of lipid-based and polymer-based nanoparticles
• Lowered cellular toxicities
• Improved colloidal stabilities

Reference

1. Van der Jeught, K.; et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget. 2015, 6(3): 1359.
2. Pichon, C.; Midoux P. Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA. Synthetic Messenger RNA and Cell Metabolism Modulation. Humana Press, Totowa, NJ. 2013, 247-274.